GSK
GSK plc
$51.38
-0.30%
$105.1B
No data for this timeframe.
Vol
Market Cap$105.1B
Cap SizeLarge Cap
Inst. Holders11 funds
Inst. Value$7.3B
Inst. Activity0 buys / 3 sells
SEC Reports3
Recent Activity
May 21, 2026
short_volume
Short Volume: GSK — 58.0% short (0.5M / 0.8M)
Short: 462,983 | Exempt: 528 | TRF Vol: 798,009 | Short Ratio: 58.0% | Off-exchange volume (dark poo
Apr 13, 2026
SEC
GSK plc repurchased 325,000 ordinary shares on April 10, 2026, as part of its ongoing buyback program, at a volume-weigh
6-K — Impact 3/10
Mar 30, 2026
SEC
GSK plc announced that China's National Medical Products Administration (NMPA) has approved Exdensur (depemokimab) for t
6-K — Impact 7/10
Mar 27, 2026
Event
ZEJULA
Supplemental Approval — Labeling — NIRAPARIB — TABLET — ORAL
Mar 26, 2026
SEC
GSK plc announced the purchase of 345,000 of its ordinary shares on 25 March 2026 at a volume-weighted average price of
6-K — Impact 3/10
Inst.
RENAISSANCE TECHNOLOGIES LLC — TRIM
1,035,572 shares ($50.8M)
Inst.
TWO SIGMA INVESTMENTS, LP — TRIM
36,300 shares ($1.8M)
Price Targets
Historical data — last covering-analyst action Jan 2026. No current recommendation available.
$57.67 (Jan 2026)
Current $51.38
Low $47.00
Median $56.00
High $70.00
8 analysts
$47.00
$70.00
Analyst Ratings
5Strong Buy
8Buy
15Hold
4Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jan 6, 2026 | Barclays | DOWNGRADE | Equal-Weight → Underweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $1.24 ▼ -3.3% | $1.24 — $1.25 | 0% YoY | 2 |
| Next Q | $1.44 ▼ -2.4% | $1.39 — $1.48 | -1% YoY | 2 |
| Current FY | $4.82 | $4.74 — $4.97 | 2% YoY | 4 |
| Next FY | $5.22 ▲ +1.1% | $5.09 — $5.45 | 8% YoY | 4 |
Latest Reports
NEUTRAL
6-K
3/10
GSK plc repurchased 325,000 ordinary shares on April 10, 2026, as part of its ongoing buyback program, at a volume-weigh
Apr 13, 2026
BULLISH
6-K
7/10
GSK plc announced that China's National Medical Products Administration (NMPA) has approved Exdensur (depemokimab) for t
Mar 30, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| DODGE & COX | $3.4B | — |
| FMR LLC | $3.3B | — |
| MORGAN STANLEY | $285.8M | TRIM |
| BANK OF AMERICA CORP | $184.1M | ADD |
| WELLS FARGO & COMPANY/MN | $124.4M | ADD |
11 institutional holders with $7.3B total value (149,697,229 shares) as of 2025-Q4. Top holders: DODGE, FMR, MORGAN. Net selling activity: 3 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | DODGE & COX | 68,517,969 | $3.4B | 45.8% | — |
| 2 | FMR LLC | 67,469,409 | $3.3B | 45.1% | — |
| 3 | MORGAN STANLEY | 5,828,663 | $285.8M | 3.9% | TRIM -28.0% |
| 4 | BANK OF AMERICA CORP /DE/ | 3,753,102 | $184.1M | 2.5% | ADD +99.8% |
| 5 | WELLS FARGO & COMPANY/MN | 2,535,850 | $124.4M | 1.7% | ADD +96.7% |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 1,035,572 | $50.8M | 0.7% | TRIM -47.9% |
| 7 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 289,888 | $14.2M | 0.2% | ADD +35.1% |
| 8 | Hillman Capital Management, Inc. | 114,336 | $5.6M | 0.1% | TRIM -28.6% |
| 9 | Tweedy, Browne Co LLC | 82,243 | $4.0M | 0.1% | — |
| 10 | TWO SIGMA INVESTMENTS, LP | 36,300 | $1.8M | 0.0% | TRIM -59.4% |
| 11 | CAUSEWAY CAPITAL MANAGEMENT LLC | 33,897 | $1.7M | 0.0% | NEAR_EXIT -97.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 1,987,953 | 1,035,572 | -47.9% | $50.8M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 89,500 | 36,300 | -59.4% | $1.8M | 2025-Q4 |
| CAUSEWAY CAPITAL MANAGEMENT LLC | NEAR_EXIT | 1,177,001 | 33,897 | -97.1% | $1.7M | 2025-Q4 |
| NORGES BANK | EXIT | 55,000 | 0 | -100.0% | $0.00 | 2025-Q3 |
| UBS Group AG | TRIM | 8,052,055 | 5,278,287 | -34.4% | $202.7M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 2,536,715 | 5,068,687 | +99.8% | $194.6M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 1,432,720 | 2,818,481 | +96.7% | $108.2M | 2025-Q2 |
| NORGES BANK | NEW | — | 55,000 | — | $2.1M | 2025-Q2 |
| CITADEL ADVISORS LLC | ADD | 1,857,714 | 2,921,574 | +57.3% | $113.2M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 2,755,193 | 1,982,153 | -28.1% | $76.8M | 2025-Q1 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 126,647 | 171,145 | +35.1% | $6.6M | 2025-Q1 |
| Hillman Capital Management, Inc. | TRIM | 231,151 | 165,143 | -28.6% | $6.4M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | NEAR_EXIT | 574,754 | 89,500 | -84.4% | $3.5M | 2025-Q1 |
| UBS Group AG | DOUBLED | 938,841 | 6,900,908 | +635.0% | $233.4M | 2024-Q4 |
| MORGAN STANLEY | TRIM | 7,953,833 | 5,726,994 | -28.0% | $193.7M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 121,603 | — | $5.0M | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 4.3/10.
NEUTRAL
6-K
3/10
GSK plc repurchased 325,000 ordinary shares on April 10, 2026, as part of its ongoing buyback progra
Apr 13, 2026
BULLISH
6-K
7/10
GSK plc announced that China's National Medical Products Administration (NMPA) has approved Exdensur
Mar 30, 2026
NEUTRAL
6-K
3/10
GSK plc announced the purchase of 345,000 of its ordinary shares on 25 March 2026 at a volume-weight
Mar 26, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Jan 2026): 41% buy across 32 analysts — 5 strong buy, 8 buy, 15 hold, 4 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Jan 2026. No current recommendation available.
$57.67 mean target (Jan 2026)
$47.00 Low
$70.00 High
| Metric | Value |
|---|---|
| Current Price | $51.38 |
| Target Low | $47.00 |
| Target Mean | $57.67 |
| Target Median | $56.00 |
| Target High | $70.00 |
| # Analysts | 8 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$1.24 | $1.24 | $1.25 | 0.3% | -3.3% | 2↑ 0↓ | $8.2B | 3.1% | 2 |
| Next Q 2026-09-30 |
$1.44 | $1.39 | $1.48 | -1.4% | -2.4% | 2↑ 0↓ | $8.9B | 3.7% | 2 |
| Current FY 2026-12-31 |
$4.82 | $4.74 | $4.97 | 2.4% | +0.3% | 2↑ 1↓ | $33.8B | 3.4% | 4 |
| Next FY 2027-12-31 |
$5.22 | $5.09 | $5.45 | 8.2% | +1.1% | 2↑ 1↓ | $35.4B | 4.8% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $1.244 | |
| 7d ago | $1.252 | -0.007 |
| 30d ago | $1.286 | -0.042 |
| 60d ago | $1.224 | +0.021 |
| 90d ago | $1.224 | +0.020 |
1 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jan 6, 2026 | Barclays | DOWNGRADE | Equal-Weight | Underweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 5 | 8 | 15 | 4 | 0 | 41% | |
| Apr 1, 2026 | 5 | 8 | 15 | 4 | 0 | 41% | |
| Mar 1, 2026 | 5 | 8 | 15 | 4 | 0 | 41% | |
| Feb 1, 2026 | 6 | 8 | 14 | 4 | 0 | 44% | |
| Jan 1, 2026 | 6 | 8 | 14 | 3 | 0 | 45% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 21, 2026
short_volume
Short Volume: GSK — 58.0% short (0.5M / 0.8M)
Short: 462,983 | Exempt: 528 | TRF Vol: 798,009 | Short Ratio: 58.0% | Off-exchange volume (dark pool + OTC)
May 20, 2026
Clinical Trial
A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older
Phase Phase 3 — COMPLETED
May 20, 2026
short_volume
Short Volume: GSK — 59.6% short (0.5M / 0.8M)
Short: 476,154 | Exempt: 4,607 | TRF Vol: 799,427 | Short Ratio: 59.6% | Off-exchange volume (dark pool + OTC)
May 19, 2026
Clinical Trial
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)
Phase Phase 3 — COMPLETED
May 19, 2026
Clinical Trial
A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype
Phase Phase 3 — COMPLETED
May 16, 2026
Clinical Trial
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)
Phase Phase 3 — COMPLETED
May 13, 2026
Clinical Trial
Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection
Phase Phase 2 — TERMINATED
May 11, 2026
short_volume
Short Volume: GSK — 58.5% short (0.7M / 1.2M)
Short: 713,516 | Exempt: 1,146 | TRF Vol: 1,220,655 | Short Ratio: 58.5% | Off-exchange volume (dark pool + OTC)
May 8, 2026
short_volume
Short Volume: GSK — 55.4% short (0.4M / 0.7M)
Short: 409,089 | Exempt: 1,821 | TRF Vol: 737,944 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)
May 7, 2026
short_volume
Short Volume: GSK — 66.8% short (0.7M / 1.1M)
Short: 739,752 | Exempt: 333 | TRF Vol: 1,107,939 | Short Ratio: 66.8% | Off-exchange volume (dark pool + OTC)
May 6, 2026
short_volume
Short Volume: GSK — 62.7% short (0.8M / 1.3M)
Short: 784,005 | Exempt: 4,088 | TRF Vol: 1,251,339 | Short Ratio: 62.7% | Off-exchange volume (dark pool + OTC)
May 4, 2026
clinical_trial_readout
T-90d Trial Readout: Flu mRNA (Formulation B1) (Phase 2)
Trial: A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above
Sponsor: GlaxoSmithKline
Phase:
May 4, 2026
short_volume
Short Volume: GSK — 56.3% short (0.7M / 1.2M)
Short: 663,519 | Exempt: 268 | TRF Vol: 1,178,502 | Short Ratio: 56.3% | Off-exchange volume (dark pool + OTC)
May 2, 2026
clinical_trial_readout
T-90d Trial Readout: Flu mRNA (Formulation B1) (Phase 2)
Trial: A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above
Sponsor: GlaxoSmithKline
Phase:
May 1, 2026
short_volume
Short Volume: GSK — 62.2% short (1.0M / 1.6M)
Short: 1,000,417 | Exempt: 659 | TRF Vol: 1,608,444 | Short Ratio: 62.2% | Off-exchange volume (dark pool + OTC)
Apr 28, 2026
short_interest
FTD: GSK — 36,129 shares ($2.0M) failed to deliver
Settlement: 20260428, Price: $54.22, FTD Value: $1,958,914.38, GSK PLC SPONSORED ADR NEW (GBR
Apr 27, 2026
clinical_trial_readout
T-90d Trial Readout: GSK5784283 (Phase 2)
Trial: A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
Sponsor: GlaxoSmithK
Apr 27, 2026
clinical_trial_readout
T-90d Trial Readout: Dostarlimab (Phase 2)
Trial: A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cance
Apr 27, 2026
short_volume
Short Volume: GSK — 56.2% short (0.6M / 1.1M)
Short: 603,740 | Exempt: 585 | TRF Vol: 1,074,394 | Short Ratio: 56.2% | Off-exchange volume (dark pool + OTC)
Apr 24, 2026
short_volume
Short Volume: GSK — 80.3% short (1.3M / 1.6M)
Short: 1,298,305 | Exempt: 1,461 | TRF Vol: 1,616,744 | Short Ratio: 80.3% | Off-exchange volume (dark pool + OTC)
Mar 27, 2026
FDA
ZEJULA
Supplemental Approval — Labeling — NIRAPARIB — TABLET — ORAL
Mar 17, 2026
FDA
LYNAVOY
Original Approval — Type 1 - New Molecular Entity — TABLET
Mar 2, 2026
FDA
Lamotrigine
WARNING: SERIOUS SKIN RASHES Lamotrigine can cause serious rashes requiring hospitalization and discontinuation of treatment. The incidence of these r
Apr 18, 2025
FDA
OJJAARA
Supplemental Approval — Labeling — MOMELOTINIB — TABLET — ORAL
Apr 18, 2025
FDA
OJJAARA
Supplemental Approval — Labeling — MOMELOTINIB — TABLET — ORAL